Loading
No description yet: the sentence for this tag has not been written. 1 record carries it: 1 protocol.
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Eye care with antibody-drug conjugates that harm the cornea: belantamab, mirvetuximab, tisotumab and enfortumab Some antibody-drug conjugates damage the front surface of the eye (the cornea), causing dry, gritty or painful eyes and blurred vision. With belantamab, mirvetuximab and tisotumab, an eye specialist examines you before and during treatment, you use eye drops on a schedule, and no contact lenses. Report any change in your sight at once: the dose can be paused or lowered, and most problems improve. | Multiple myeloma, Relapsed or refractory multiple myeloma, Platinum-resistant ovarian cancer | none | protocol, antibody-drug-conjugate, supportive-care |